Application value and clinical significance of AMACR, p63 and Ki-67 immunohistochemistry in pathological diagnosis of prostate cancer
10.3760/cma.j.cn431274-20240108-00057
- VernacularTitle:AMACR、p63及Ki-67三联免疫组化检测在前列腺癌病理诊断中的应用价值及临床意义
- Author:
Yinghui GU
1
;
Yanlin SHI
1
;
Xinyan FANG
1
Author Information
1. 启东市中医院病理科，启东 226200
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Immunohistochemistry;
Alpha-methylacyl-CoA racemase;
P63 protein;
Ki-67 antigen
- From:
Journal of Chinese Physician
2025;27(1):96-101
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the value and significance of α-methylacyl-CoA racemase (AMACR), p63 and Ki-67 immunohistochemical detection in the pathological diagnosis of prostate cancer.Methods:A total of 156 archived prostate biopsy paraffin samples collected from Qidong Hospital of Traditional Chinese Medicine from June 2022 to August 2023 were selected as research materials. The expression of AMACR, p63 and Ki-67 in 48 cases of prostate cancer, 32 cases of high-grade prostatic intraepithelial neoplasia, 26 cases of low-grade prostatic intraepithelial neoplasia and 50 cases of prostatic hyperplasia were detected by immunohistochemistry. The correlation between the expression of AMACR, p63 and Ki-67 and the clinical and pathological features of prostate cancer patients, as well as their diagnostic efficacy for prostate cancer were analyzed.Results:There were statistically significant differences in the positive expression rates of AMACR, p63 and Ki-67 among the samples of different groups (all P<0.05). The positive expression rate of AMACR in the biopsy samples of prostate cancer group was 100%, and the high expression rate was 81.25%, which was significantly higher than that of the other three groups. The negative expression rate of p63 was 97.92%, which was significantly higher than the other three groups. The positive expression rate of Ki-67 was 81.25% and the high expression rate was 54.17%, which was significantly higher than the other three groups. The expression of AMACR was related to tumor length, TNM stage, differentiation degree and Gleason score of prostate cancer patients. The high expression rate of AMACR in patients with tumor size ≥1.5 cm, stage Ⅱ to Ⅲ, medium and highly differentiated tumors with Gleason score 8-10 was significantly higher than those with tumor size <1.5 cm, stage Ⅰ, low differentiation, and Gleason score 2-7 (all P<0.05). Ki-67 expression was correlated with tumor length, differentiation degree, lymph node metastasis and Gleason score in prostate cancer patients. The high expression rate of Ki-67 in patients with tumor size ≥1.5 cm, medium and highly differentiated tumors with lymph node metastasis and Gleason score 8-10 was significantly higher than that in patients with tumor size<1.5 cm, low differentiation, no lymph node metastasis and Gleason score 2-7 (all P<0.05). The expression of p63 was not correlated with the clinical and pathological features of patients with prostate cancer (all P>0.05). The sensitivity and negative predictive value of AMACR positive/p63 negative/Ki-67 positive combined diagnosis of prostate cancer were 100.00%, and the specificity was 81.82%. Conclusions:AMACR, p63 and Ki-67 in prostate biopsy samples can be used as good biomarkers for the diagnosis or exclusion of prostate cancer, and the combined detection can improve the diagnosis accuracy of prostate cancer.
